

CURRENT CLINICAL TRIALS

Mercer University School of Medicine Clinical Research Department is proud to offer a large number of clinical trials for patients and potential patients. Our researchers start new trials throughout the year. Check our website at <https://medicine.mercer.edu/research/clinical-research/> for a list of currently enrolling studies. For questions regarding a specific clinical trial, please contact the Clinical Research Director at 478-301-5846 to be directed to the appropriate study coordinator.

STUDIES IN FOLLOW UP:

- **CROWN (221611):** A Phase 3b, open label, randomized, standard-of-care control arm, multicenter, superiority study evaluating the efficacy, safety and tolerability of injectable CAB LA + RPV LA in viremic participants living with HIV-1.
- **EYEWITNESS (219516):** A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bicitgravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed.
- **GS-US-563-5925/ISLEND-1:** A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bicitgravir/Emtricitabine/Tenofovir (B/F/TAF).
- **GS-US-563-5926/ISLEND-2:** A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care.
- **GS-US-621-6289/ARTISTRY-1:** An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bicitgravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens.
- **GS-US-621-6290/ARTISTRY-2:** Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bicitgravir/Lenacapavir Versus Biktarvy® (Bicitgravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV 1.
- **GS-US-695-7156/WONDERS-2:** An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS 1720 in Combination With GS 4182 Versus Biktarvy in Treatment Naïve People With HIV-1.
- **MK-8591A-052:** A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants with HIV 1 Who Are Virologically Suppressed on Bicitgravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).
- **MK-8591A-053:** A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants.
- **MK-8591A-054:** A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study.